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Abstract: Hand, foot, and mouth disease (HFMD) commonly produces herpangina, but fatal
neurological complications have been observed in children. Enterovirus 71 (EV-A71) and
Coxsackievirus 16 (CV-A16) are the predominant viruses causing HFMD worldwide. With rising
concern about HFMD outbreaks, there is a need for an effective vaccine against EV-A71 and CV-A16.
Although an inactivated vaccine has been developed against EV-A71 in China, the inability of the
inactivated vaccine to confer protection against CV-A16 infection and other HFMD etiological agents,
such as CV-A6 and CV-A10, necessitates the exploration of other vaccine platforms. Thus, the
antigenic peptide-based vaccines are promising platforms to develop safe and efficacious multivalent
vaccines, while the monoclonal antibodies are viable therapeutic and prophylactic agents against
HFMD etiological agents. This article reviews the available information related to the antigenic
peptides of the etiological agents of HFMD and their neutralizing antibodies that can provide a basis
for the design of future therapies against HFMD etiological agents.
Keywords: vaccine; antigenic peptide; neutralizing antibodies
1. Introduction
Hand, foot, and mouth disease (HFMD) is a prevalent paediatric infectious disease that is caused
by a variety of enteroviruses [1–4]. HFMD has become a major public health threat that leads to serious
morbidity and mortality in Asia-Pacific. In 2017, a total of 1,952,435 HFMD cases were recorded in
China [5]. Enterovirus 71 (EV-A71) and Coxsackievirus 16 (CV-A16) are the main HFMD causative
agents of mild HFMD. However, some EV-A71 strains have been known to be associated with fatal
neurological complications [1,2]. In recent years, many HFMD outbreaks are associated with emerging
enteroviruses, including CV-A6, CV-A8, and CV-A10 [3,4,6]. Together with EV-A71 and CV-A16, these
enteroviruses have been shown to co-circulate in many HFMD outbreaks, which may result in viral
co-infections and genomic recombination [7,8].
With rising concern about HFMD outbreaks, there is an urgent need for a vaccine against EV-A71
to be produced that is approved by the United States Food and Drug Administration (FDA) or
European Medicines Agency (EMEA). The inactivated EV-A71 vaccine has typically been used as
the main strategy for vaccine design [9]. China’s FDA has issued drug certificates and production
licenses for the inactivated vaccines from 3 companies, namely, Sinovac, Vigoo, and Chinese Academy
of Medical Sciences (CAMS) [9]. Sinovac reported that the efficacy of their inactivated vaccine against
EV-A71-associated HFMD cases was 94.8% during the 12-month surveillance period [10]. Besides
that, CAMS and Vigoo reported 97.4% and 90.0% vaccine efficacy against EV-A71-associated HFMD,
respectively [11,12]. Despite the promising results revealed by the safety and efficacy studies, the
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licensed vaccines are incapable of eliciting sufficient cross-neutralizing antibodies against the other
HFMD causative agents, such as CV-A16, CV-A6 and CV-A10 [9]. Therefore, it is imperative to
explore other vaccine strategies to produce a safe and effective vaccine against multiple HFMD
etiological agents.
A comprehensive understanding of the antigenic peptides that could elicit neutralizing antibodies
will greatly help in the design of an effective vaccine. We discuss the structural analysis of EV-A71 viral
particles to identify possible foreign peptide insertion sites to develop a multivalent vaccine based on a
virus-like particle (VLP) platform. Lastly, we suggest some strategies to develop multivalent vaccines
against multiple viruses that can cause HFMD.
2. Etiological Agents of HFMD
HFMD etiological agents (EV-A71, CV-A16, CV-A6, and CV-A10) belong to the Picornaviridae
family, within species A of the Enterovirus genus [13]. The Enterovirus A species possesses
non-enveloped virus particles with symmetrical 20–30 nm icosahedral capsids. The viral particle
contains a single-stranded positive sense 7.4 Kb ribonucleic acid (RNA) with a single open reading
frame, which is flanked by a 5′-untranslated region (5′ UTR) and a 3′ UTR with a poly(A) tail.
Enterovirus A encodes a polyprotein of approximately 2100 amino acids that will be further cleaved
to form three precursor proteins, termed as P1, P2, and P3. Structural viral proteins, named as VP1,
VP2, VP3, and VP4, are the products of P1 cleavage. Besides that, P2 and P3 cleavage form seven
non-structural proteins, namely 2A, 2B, and 2C, which are derived from P2, and 3A, 3B, 3C, and 3D,
which are derived from P3. Enterovirus A viral capsids are formed by 60 protomers of the structural
viral proteins; each protomer consists of VP1, VP2, VP3, and VP4 [14]. The external capsid surface
is formed by VP1, VP2, and VP3, while VP4 is located inside the capsid [14]. VP1, VP2, and VP3 are
structurally similar to one another, each consisting of eight-stranded β-barrels.
Comprehensive structural and biochemical studies reported five recognizable viral particles
throughout the Enterovirus A lifecycle. They are the putative pro-capsid, the pro-virion, the mature
infectious virus, the “A-particle”, and the empty capsid. Particle assembly commences in the cytoplasm
where the protomer is formed by viral structural proteins VP0, VP1, and VP3. Five protomers will then
assemble to form the pentameric subunit, which ultimately self-assembles to form the 60 protomer
pro-capsid. The pro-capsid will acquire the viral genome to form the pro-virion. After the formation
of the pro-virion, VP0 will be autocatalytically cleaved into VP2 and VP4 to form the mature virions
that are released from infected cells. The mature virions will bind to neighbouring host receptors on
the cell surface and begin the two-step uncoating process, which are (1) the formation of an expanded
and altered particle, termed as “A-particle”, which is primed for genome release, and (2) the release
of RNA into the host cell generating an intact empty capsid. VP4 is essential during the uncoating
process as it is inserted into the membrane to form a channel in which the RNA can be released into
the host cell cytoplasm [15–19].
The mature virus particles and the empty capsid are predominantly produced during EV-A71
natural infection. These two particles can be separated using continuous sucrose gradient
ultra-centrifugation. The empty capsids have ~5% larger diameter than the mature virus particles [19].
Crucially, both viral particles displayed distinct antigenic properties, whereby the empty capsids are
hypothesised to act as baits for host immune evasion [20].
3. Neutralizing Epitope Mapping
3.1. EV-A71 Neutralizing Epitope Mapping
Over the years, a number of linear neutralizing epitopes in the enteroviruses causing HFMD have
been reported by many research groups. These reported linear and conformational epitopes were
mostly mapped to the enterovirus structural proteins VP1, VP2, VP3, and VP4. We have summarized
the reported linear neutralizing epitopes from EV-A71 and CV-A16 in Table 1.
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VP1 is a capsid protein comprising 297 amino acids and is located at the most external part of the
viral capsid. VP1 was the first EV-A71 antigen found to contain important epitopes that contribute to
the neutralization of the virus. Initially, Wu et al. (2001) found that immunization using a recombinant
VP1 protein of EV-A71 expressed in E. coli conferred protection against lethal EV-A71 infection in
neonatal mice [21]. Subsequently, Foo et al. (2007) tested the neutralizing capabilities of the antisera
elicited by ninety-five diphtheria toxoid-conjugated synthetic peptides encompassing the entire VP1
region [22]. Two of the synthetic peptides designated SP55 spanning amino acids 163–177 of VP1 and
SP70 spanning amino acids 208–222 of VP1 elicited high titres of neutralizing antibodies belonging
to the IgG1 subtype against EV-A71. The SP55 epitope was a weaker immunogen, as the specific
IgG response in mice was relatively low. Studies carried out by Xu et al. (2015) and Liu et al. (2011)
confirmed SP70 as a neutralizing linear epitope of EV-A71 [23,24]. In another study, sixty-three
synthetic peptides were synthesized and used to map the EV-A71 linear B-cell epitopes [25]. This study
revealed the synthetic peptide designated PEP27 spanning amino acids 142–156 of VP1 carried the
EV-A71 IgM-specific immune-dominant epitope. In addition, another epitope denoted as PEP23
spanning amino acids 41–55 of VP1 was identified as the EV-A71 IgG cross-reactive immune-dominant
epitope. Gao et al. (2012) also identified the same region spanning amino acids 43–54 of VP1 as the IgG
epitope [26]. In addition, they identified the region spanning amino acids 40–51 of VP1 as the EV-A71
IgM epitope [26].
VP2 is another capsid protein consisting of 254 amino acids. Epitope mapping studies revealed
that VP2 has one neutralization epitope located in the region spanning amino acids 134–155. Liu et al.
(2011) reported the region corresponding to amino acids 136–150 of VP2 (designated as VP2-28 or
SP28) was able to bind an EV-A71 cross-neutralizing antibody MAB979 [23]. Subsequently, Kiener
et al. (2012) reported that the region spanning amino acids 141–155 of VP2 is a cross-neutralizing
epitope [27]. They identified a single amino acid mutation within the region (S144T) that led to the
loss of VP2 antigenicity against EV-A71 strain C4. The same region (amino acids 141-155 of VP2) was
also identified by Xu et al. (2014) to be a cross-neutralizing epitope [28].
EV-A71 VP3 protein comprises 245 amino acids. Unlike other viral structural proteins, no linear
neutralizing epitope has been mapped in VP3. There is a conformational epitope within the VP3
protein known as the “Knob” region, which was identified during neutralizing monoclonal antibody
screening in mice [29]. The conformational epitope spanning amino acids 55 to 69 is highly conserved
among EV-A71 sub-genotypes and was recognized by monoclonal antibody 10D3. In addition, another
study that immunized mice with EV-A71 sub genotype B4 mapped a conformational epitope to the
highly conserved amino acid 74 of VP3, whereby this region was found to be recognized by 5H7,
a therapeutic IgG antibody [30].
VP4 protein consists of 69 amino acids. VP4 adopts an extended conformation and is localized
inside the virion. It is the most conserved viral structural protein. Hence, there were some studies
that focussed on mapping neutralization epitopes within the VP4 protein to produce a universal
vaccine against all EV-A71 sub-genotypes. Zhao et al. (2013) identified the N-terminal residues 1–20 of
EV-A71 VP4 designated as VP4N20 to be a neutralizing epitope [31]. In their study, they fused VP4N20
to hepatitis B core antigen. The chimeric fusion protein was expressed in E. coli and was found to
spontaneously assemble into chimeric virus-like-particles (VLPs). Immunization with the chimeric
VLPs presenting VP4N20 was able to elicit anti-VP4N20 antibody response. The anti-chimeric VLP
sera were able to confer protection against EV-A71 challenge in neonatal mice.
3.2. CV-A16 Epitope Mapping
Unlike EV-A71, much less is known about neutralizing linear epitopes in CV-A16. Similar to
EV-A71, most of the experimentally proven neutralizing linear epitopes were mapped to the VP1
protein. Chong et al. (2012) performed the first study to map linear neutralizing epitopes in CV-A16
viral particles [32]. They identified a single linear immune-dominant epitope localized in the VP3
protein of CV-A16, spanning amino acids 176–190. However, the epitope was weakly recognized
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by mouse anti-sera raised against formalin-inactivated CV-A16 [32]. The failure to map more linear
neutralizing epitopes in this study could be the result of the formalin treatment that changed the
native surface exposed epitopes of formalin-inactivated CV-A16. The altered surface could lead to
either (1) the formalin-inactivated CV-A16 losing its immunogenicity, and thus the failure to elicit
antibodies, or (2) the antibodies elicited against the formalin-inactivated CV-A16 altered surface could
not recognize the native amino acids of the peptides that were screened. Indeed, an earlier study
performed by Liu et al. (2012) reported immunization with CV-A16 VLPs consisting of VP0, VP1,
and VP3 potently elicited CV-A16 specific antibody responses. The anti-VLP sera were able to confer
protection against lethal CV-A16 challenge in mice, suggesting the presence of neutralizing epitopes in
the structural viral proteins [33]. Subsequently, using a set of 95 synthetic peptides encompassing the
entire VP1 for reactivity with neutralizing murine antisera raised against CV-A16 VLPs, they identified
six linear neutralizing epitopes localized in the VP1 protein of CV-A16 [34]. The six peptides were
PEP32 (amino acids 94–108), PEP37 (amino acids 109–123), PEP55 (amino acids 163–177), PEP63 (amino
acids 187–201), PEP71 that corresponded to SP70 in EV-A71 (amino acids 211–225), and PEP91 (amino
acids 271–285) [34]. Other than VP1 and VP3, a neutralizing epitope was experimentally mapped to
the N-terminal region of VP4 corresponding to the VP4N20 peptide in EV-A71 [35].
Table 1. Experimentally mapped linear epitopes in the structural proteins of EV-A71 and CV-A16.
Virus Region Name and Position Peptide Sequences Epitopes Ref.
EV-A71
VP1
PEP23 (aa 41–55) TGEVPALQAAEIGAS IgG [25]
VP1–15 (aa 43–54) KVPALQAAEIGA IgG [26]
VP1–14 (aa 40–51) DTGEVPALQAAE IgM [26]
VP1 PEP27 (aa 142–156) PTGEVVPQLLQYMFV IgM [25]
VP1 SP55 (aa 163–177) PESRESLAWQTATNP IgG [22]
VP1
SP70 (aa 208–222) YPTFGEHKQEKDLEYC IgM and IgG [22]
VP1 (aa 208–222) YPTFGEHKQEKDLEYC IgG [24]
VP1–43 (aa 211–220) FGEHKQEKDL IgG [23]
VP2
VP2–28 (aa 136–150) AGGTGTEDSHPPYKQ IgG [23]
7C7 (aa 142–146) EDSHP IgG [28]
VP2 (aa 141–155) TEDSHPPYKQTQPGA IgG [27]
VP4 VP4N20 (aa 1–20) GSQVSTQRSGSHENSNSATE Neutralizing [31]
CV-A16
VP1
PEP32 (aa 94–108) TMPTMGTQNTDGYAN IgG [34]
PEP37 (aa 109–123) WDIDLMGYAQLRRKC IgG [34]
PEP55 (aa 163–177) PTSRDSFAWQTATNP IgG [34]
PEP63 (aa 187–201) PAQVSVPFMSPASAY IgG [34]
PEP71 (aa 211–225) FGEHLQANDLDYGQC IgG [34]
PEP91 (aa 271–285) YLFKTNPNYKGNDIK IgG [34]
VP3 VP3–41 (aa 176–190) HYRAHARAGYFDYYT IgG [32]
VP4 VP4N20 (aa 1–20) GSQVSTQRSGSHENSNSASE Neutralizing [35]
aa = amino acid.
3.3. CV-A6 and CV-A10 Epitope Mapping
Apart from EV-A71 and CV-A16, other coxsackieviruses, such as CV-A6 and CV-A10, have
been reported as emerging viruses to cause large scale outbreaks of HFMD [3,4]. Since these viruses
are the emerging causative agents for HFMD, studies related to these viruses were reported more
recently [36–39]. In one of the studies, Xu et al. (2017) determined the near-atomic resolution structure
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of CV-A6 A-particle in complex with a neutralizing antibody [38]. Detailed inspection of the structure
mapped an immune-dominant neutralizing epitope to the surface loops of VP1, including the BC,
DE, EF, and HI loops. Besides that, another study provided further insight into the structural basis of
CV-A10 in complex with a neutralizing antibody designated 2G8 [36]. The atomic complex structure
revealed that the Fab of 2G8 binds to a border region across three capsid proteins, VP1, VP2, and VP3.
Unlike EV-A71 and CV-A16, no linear epitope mapping experiments were performed for CV-A6 and
CV-A10. Due to their overall similarities, it is possible that the amino acids in CV-A6 and CV-A10
corresponded to the linear neutralizing epitopes identified in EV-A71 and CV-A16.
4. Antigenic Peptide-Based Vaccine
Linear peptides are attractive vaccine candidates as they may induce highly targeted immune
responses, albeit its usage in isolation are often weakly immunogenic [40]. Due to their relatively
small size, peptide vaccine manufacturing is relatively safe and cost effective in comparison to
conventional vaccines, such as the live-attenuated and the whole-inactivated vaccines [40]. In the
case of HFMD, many studies were performed to develop linear neutralizing peptide-based vaccines
against the main etiological agent of HFMD, such as EV-A71 and CV-A16. Although EV-A71
formaldehyde-inactivated vaccines were recently licensed in China, the inability of these inactivated
vaccines to confer protection against other HFMD causative agents, such as CV-A16, CV-A6, and
CV-A10, necessitates the exploration of other vaccine platforms, such as multi-epitope peptide vaccines.
Another advantage of peptide-based vaccine is the possibility of diminishing the
antibody-dependent enhancement (ADE) of viral infection. ADE refers to sub-neutralizing or
non-neutralizing antibodies produced from previous primary infections or through maternal-foetal
transfer that could worsen subsequent infections leading to enhanced disease severity. During
secondary viral infection, the binding of pre-existing non-neutralizing antibodies to the virus enhances
the entry of the virus; through the interaction between an antibody bound virus with Fc receptors (FcR)
of myeloid cells, such as natural killer cells, macrophages, and B lymphocytes [41]. In the context of
EV-A71 infections, ADE has been observed in both clinical and experimental settings [42–44]. In a study
describing human IgG subclass response to EV-A71 infections, Cao et al. (2013) found the neutralizing
activity of human intravenous immunoglobulin is mainly mediated by the IgG1 subclass [45]. Besides
that, they found that IgG2 subclass also displayed neutralizing activity, albeit to a lesser extent as
compared to IgG1. In contrast, IgG3 was found not to have neutralizing activity. Furthermore, they
demonstrated that the IgG3 subclass enhanced EV-A71 infection [45]. These findings are critical for the
rational design of peptide-based vaccines that only induce high levels of the neutralizing antibody
responses (e.g., IgG1 and IgG2), but not the non-neutralizing antibody responses (e.g., IgG3), towards
EV-A71 or other HFMD etiological agents.
4.1. Peptide-Based Vaccines Against EV-A71
Several studies reported the efficacies of linear antigenic peptide-based vaccines against
EV-A71. For instance, a diphtheria toxoid-conjugated synthetic peptide comprising the EV-A71
SP70 neutralizing epitope was able to confer 80% passive protection in mice upon lethal challenge and
elicited cross protective neutralizing antibodies (1:32) against EV-A71 sub-genotypes B2, B5, C2, and
C4 [46]. Subsequently, Tian et al. (2012) reported the incorporation of the EV-A71 SP70 epitope within
surface-exposed domains of the adenovirus type 3 hexon [47]. The construct was able to elicit humoral
responses specific to the SP70 epitope. They also found that antisera raised against the construct were
able to confer 70% protection of mice upon lethal EV-A71 challenge. Even though the protection was
less than the diphtheria toxoid-conjugated EV-A71 SP70, this study demonstrated the possibility of
using adenovirus to display the EV-A71 neutralizing epitope.
Another study focussed on the design of a tandem multi-linear neutralizing peptide vaccine.
Li et al. (2014) designed a novel recombinant tandem multi-linear neutralizing epitope of EV-A71
designated as mTLNE [48]. The mTLNE comprised three linear neutralizing epitopes of SP55, SP70,
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and SP28, which were sequentially connected by a (Gly4Ser)3 linker. The mTLNE also contained
thioredoxin (Trx) at the N-terminal to improve solubility and immunogenicity. Additionally, six
histidine (His) were added at the C-terminal for affinity chromatography purification of the E. coli
expressed proteins. Following immunization in adult mice, the mTLNE elicited EV-A71 specific IgG
antibodies. Passive transfer of the anti-mTLNE sera conferred 100% protection against lethal EV-A71
challenge in mice. This is a marked improvement in comparison to the 80% protection conferred by the
anti-diphtheria toxoid-conjugated EV-A71 SP70 sera and 70% protection conferred by antisera raised
against recombinant adenovirus carrying the SP70 epitope in previous lethal challenge studies [46,47].
Although the neutralizing titres elicited by SP55, SP70, and the mTLNE peptide vaccine were relatively
low in comparison to EV-A71 VLPs and the formaldehyde-inactivated EV-A71, the advantage of this
approach should be examined. For instance, immunization studies in mice revealed that SP55, SP70,
and the mTLNE peptide vaccine induced robust IgG1 response and not IgG3 [22,48]. This indicated
these peptides would not contribute to the ADE phenomenon if incorporated into future peptide-based
vaccine development.
4.2. EV-A71/CV-A16 Peptide-Based Bivalent Vaccines
Consistent with the low amino acid sequence identity of 20.7% between EV-A71 and CV-A16
capsid proteins (VP1, VP2, VP3, and VP4), vaccine candidates that were able to confer protection
against EV-A71 were weakly cross-protective against CV-A16 infection [49,50]. For instance, VLPs
and inactivated EV-A71 or CV-A16 monovalent vaccines failed to provide sufficient cross protection
against their enteroviral counterparts [50]. To address this issue, an EV-A71/CV-A16 bivalent vaccine
was produced by mixing equivalent doses of EV-A71 and CV-A16 VLPs or the inactivated EV-A71 and
CV-A16 viruses. The EV-A71/CV-A16 bivalent vaccine was able to elicit cross-neutralizing antibodies
and the immune sera from vaccinated animals could confer passive protection against EV-A71 and
CV-A16 lethal challenges. However, the large-scale growth and production of either of the viruses or
the VLPs constituting the bivalent vaccine will not be cost effective. Moreover, chemical treatments
have been shown to alter the antigenic surface of CV-A16 [32,51]. Considering these problems, it is
better to produce a multi-epitope antigen or a chimeric antigen that can elicit neutralizing antibodies
against both EV-A71 and CV-A16.
Based on the 80% sequence identity between SP70 and PEP71 epitopes, coupled with structural
studies that revealed these epitopes were displayed on the virion surface, Zhao et al. (2015) designed
a peptide-based EV-A71/CV-A16 bivalent vaccine [52–55]. They constructed a chimeric EV-A71
VLP designated as ChiEV-A71 VLP, in which the SP70 of EV-A71 was replaced with PEP71 of
CV-A16 [52]. The yeast expressed ChiEV-A71 VLPs were found to induce robust Th1/Th2-dependent
immune responses against EV-A71 and CV-A16 in mice. Besides that, passive immunization with
anti-ChiEV-A71 VLP sera conferred full protection against lethal EV-A71 and CV-A16 challenges.
Subsequent studies provided insights into the structural basis of EV-A71 and CV-A16 neutralizations
by ChiEV-A71 VLPs [56]. The substitution of the SP70 segment in EV-A71 with the corresponding
PEP71 region from CV-A16 led to surface charge potential of the modified region to shift from negative
to neutral. The surface charge potential shifts coupled with the amino acid changes (K215L, E217A,
K218N, E221D) most likely accounted for ChiEV-A71 VLP dual neutralization capabilities of EV-A71
and CV-A16. Importantly, this is the first study utilizing an antigenic peptide to produce a bivalent
vaccine in the form of a chimeric VLP.
In another effort to produce a bivalent vaccine, Xu et al. (2015) used hepatitis B virus core protein
to construct a bivalent chimeric VLP presenting the SP70 epitope and VP2 epitope spanning amino
acids 141 to 155 of EV-A71 [24]. They discovered that the chimeric VLP designated as HBc-E1/2
elicited high IgG and neutralization titres against both EV-A71 and CV-A16. Furthermore, passive
immunization with HBc-E1/2 protected neonatal mice against lethal EV-A71 and CV-A16 challenges.
The VP2 epitope (amino acids 141 to 155) was shown to be immune-dominant in both EV-A71 and
CV-A16. They found that the anti-VP2 epitope elicited antibodies that could bind to both EV-A71 and
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CV-A16 viral particles, whereas antibodies from the anti-SP70 epitope did not bind to CV-A16 viral
particles. These studies highlighted the possibility of employing linear epitopes identified from both
EV-A71 and CV-A16 to produce a bivalent vaccine against both viruses.
4.3. Peptide Insertion Sites in EV-A71 VLP
To date, VLP is one the most suitable and widely used platform technologies to display antigenic
peptides for vaccine development [57]. Advantages of VLP as a vaccine platform include: (1) its
20–100 nm diameter size which allows easy entry into the lymphatic vessels, passive drainage to the
subcapsular lymph nodes, and optimal uptake by antigen presenting cells; and (2) the geometry that
contributes to their ability to activate B-cells as the epitopes presented on the repetitive and rigid
structures of VLPs could extensively interact with antigen presenting cells, leading to stimulation of
B-cells and elicitation of robust antibody responses. Besides directly substituting the corresponding
regions in a VLP with another region from a different virus to form a bivalent vaccine, regions in
the VLP that were exposed or externalized on the viral capsid could be exploited to display B-cell
epitopes from other enteroviruses to form multivalent vaccines. A recent study has reported repeated
administration of an EV-A71 VLP vaccine which were well tolerated in rabbits and immunogenic.
This further supported the use of EV-A71 VLP as a vaccine platform to display antigenic peptides [58].
In EV-A71 research, Arita et al. (2007) firstly identified that a histidine tag could be inserted into
the BC-loop of VP1 between amino acids 100 and 101 without affecting the infectivity of the engineered
EV-A71 [59]. Subsequently, Lyu et al. (2013) inserted nucleating peptides at the same position to
produce a thermostable attenuated EV-A71 vaccine [60]. The insertion of peptides endowed the virus
with the capacity to generate an exterior calcium phosphate shell. Intriguingly, the modified surface
enabled the virus to exhibit improved thermostability and immunogenicity. They also determined the
structures of two naturally occurring empty EV-A71 particles, one from a clinical C4 strain and the
other from the recombinant virus containing a foreign peptide in the BC loop of VP1 [55]. Detailed
inspection of the structures revealed the inserted foreign peptide was well displayed on the viral
particle surface without significant structural perturbations of the viral capsid. In addition, comparison
of the uncoating intermediates of EV-A71 and recombinant EV-A71 virus demonstrated that the foreign
peptide insertion did not affect the virus uncoating process. Furthermore, the crystal structure of
yeast-produced EV-A71 revealed that the VLP produced using the yeast expression system (PDB
code: 4YVS) shared very high structural similarity with the empty particles (PDB code: 4RQP).
Superimposition using PyMOL of the VP1, VP3, and VP0 onto the corresponding viral structural
proteins on EV-A71 empty virus particle resulted in a calculated root mean square deviation (r.m.s.d)
of 0.504 Å over 560 Cα atoms. Based on the structural and functional evidence, the BC-loop of EV-A71
was identified to be a suitable peptide insertion site to develop multivalent vaccines.
In addition to the BC-loop, other insertion sites should be identified to produce trivalent or
tetravalent HFMD vaccines against other HFMD causative agents. Based on the available EV-A71
structures in the protein database, the EF loop of VP0 (or VP2) corresponding to amino acids 202 to
214 might be another suitable site for foreign peptide insertion (Figure 1). This region is located at the
surface of the viral capsid. As demonstrated previously by Lyu et al. (2015), the surface-exposed loop
was an ideal site for foreign linear peptide insertion [55]. However, peptide insertions might affect
the ability of recombinant protein to assemble into VLPs. Thus, structural and functional validations
using techniques such as X-ray crystallography and Cryo-electron microscopy are crucial to ensure
that the peptide insertions do not perturb the overall structure of the VLP.
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Figure 1. Position of VP1 BC loop and VP2 EF loop on the EV-A71 viral capsid. Representation of the
EV-A71 VLP viral capsid. VP1, VP2 and VP3 structural proteins are shown in grey. The VP1 BC loop
and VP2 EF loop are shown in black and labelled. PDB code: 4RQP.
4.4. Tetravalent Peptide-Based HFMD Vaccine
Previous attempts were made to use the traditional VLP-based platform to produce a tetravalent
HFMD vaccine. For instance, Zhang et al. (2018) produced each single VLP of EV-A71, CV-A16,
CV-A6, and CV-A10 using a baculovirus-insect cell expression system, and then combined them to
formulate a tetravalent HFMD vaccine [61]. They found the tetravalent vaccine elicited antigen specific
and long lasting antibody responses in addition to passive protection conferred by the tetravalent
vaccine-immunized sera against single or mixed infections with EV-A71, CV-A16, CV-A6, and CV-A10
in mice. However, large scale productions of the four VLPs will be costly and time-inefficient in
comparison to the production of a single VLP carrying peptide epitopes from the four different viruses.
Similar to EV-A71 and CV-A16, other Enterovirus A serotypes were found to carry the SP70 motif.
Based on sequence analysis of several Enterovirus A serotypes, the SP70 motif can be denoted as
YPTFGX1HPX2X3X4X5X6X7Y (Figure 2). The motif consists of the highly conserved amino acids Tyr,
Pro, Thr, Phe, Gly (YPTFG), followed by X1 (which can either be polar uncharged amino acids or
negatively charged amino acids), the highly conserved His and Pro, followed by X2, X3, X4, X5, X6, X7,
and ending with a highly conserved Tyr. Amino acids X2 and X3 can be any amino acid, X4 and X7 can
be any of the polar uncharged or charged amino acids, X5 can either be an Asp or an Asn, while X6 can
be any hydrophobic amino acid (Leu, Val, Phe, Ile).
Based on previous findings of the bivalent EV-A71/CV-A16 vaccine, the SP70 linear epitope from
EV-A71, CV-A16, CV-A6, and CV-A10 could be incorporated into a VLP to produce a tetravalent
HFMD vaccine [52]. Inspection of the viral particle structures of EV-A71, CV-A16, CV-A6, and CV-A10
revealed all viral particles to be structurally very similar. Crucially, the SP70 motif was present within
the GH loop of each of the viral particles, hence, it is possible to insert the SP70 motif of each virus
into a single VLP. For example, the EV-A71 VLP is a suitable VLP to be used to construct the HFMD
tetravalent vaccine, as it is the most widely studied amongst all the enteroviral VLPs. In addition to
the substitution of the SP70 motif of EV-A71 with the corresponding CV-A16 epitope in the EV-A71
VLP, the SP70 motif from CV-A6 could also be inserted into the BC-loop insertion site and another
SP70 motif from CV-A10 could be inserted into the site in the EF loop of VP0 or VP2. The insertion site
should be experimentally and structurally validated to ensure that the SP70 peptide insertion does not
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disrupt the global structure of the EV-A71 VLP. Furthermore, studies should be performed to confirm
that the SP70 motifs of both CV-A6 and CV-A10 are able to elicit neutralization antibodies, similar to
the SP70 motif present in either EV-A71 or CV-A16.
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Another approach that should be considered is to expand the ta dem multi-li r neutralizing
epitope (mTLNE) vaccine strategy to produce a multivalent vacci e. It is possible to design a peptide
vaccine containing multiple SP70 epitopes from EV-A71, CV-A16, C 6, and CV-A10 that are linked
together to produce a tetravalent HFMD peptide-based v ccine th t is protective against the four
viruses. Besides that, the mTLNE accine approach could be presented on nanoparticles r on VLPs
which might mprove the immunogenicity and efficacy of the tetravalent vaccine.
Besides EV-A71 VLP, hepatit B core antigen virus-like-particle (HBcAg-VLP) is an attractive
lternative VLP to display multipl epitopes o HFMD etiological agents. HBcAg-VLP is one of the best
c aracterized VLPs. It possesses th ee possible peptide or ant gen insertion sites, which are located at
the N terminus, the C erminus, and the immune-dominant l op region (between Asp79 and Pro79) [62].
For the N and C termini insertions, a maximum of 100 amino acids can be ins r ed into each inser on
site [62]. Although the inser ed antigens at the C and N termini will be immunogenic, HBcAg-VLP will
retain its strong intrinsic immunogenicity as immune responses would target the immune-dominant
loop region. Therefore, to achieve the highest immunogenicity, the insertion at the immune-dominant
loop region is most favourable. Insertion of an antigen within the immune-dominant loop region will
abrogate HBcAg-VLP intrinsic immunogenicity and directs immune responses towards the inserted
foreign antigen. Besides that, the antigen insertion capacity of this region is very high, as demonstrated
by the successful insertion of the green fluorescent protein (238 aa) and the dimeric outer surface
lipoprotein C of Borrelia burgdorferi (~210 aa) [63,64].
Crucially, Wu et al. (2017) demonstrated that HBcAg-VLP inserted with two linear epitopes
from EV-A71 (SP70 epitope and amino acids 141-155 of VP2) and one epitope from glycoprotein E
(amino acids 121–135) of varicella-zoster virus (VCV) in a tandem manner was able to self-assemble
into a VLP [65]. The VLP designated as HBc-V/1/2 elicited a balanced antibody response towards
the three epitopes. Importantly, the HBc-V/1/2 antisera could neutralize EV-A71, CV-A16, and VCV.
Moreover, the HBc-V/1/2 antisera were able to protect neonatal mice against lethal challenges of
EV-A71 and CV-A16. Based on these studies, the combination of the HBcAg-VLP platform with the
mTLNE strategy might yield an effective tetravalent HFMD vaccine against EV-A71, CV-A16, CV-A6,
and CV-A10. For instance, a highly immunogenic linear epitope, such as the SP70 epitope from each of
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the four HFMD etiological agents, could be linked together to form a mTLNE. The mTLNE can be
inserted into the immune-dominant region of HBcAg-VLP to develop a multivalent HFMD vaccine.
Theoretically, there are many advantages of using HBcAg-VLP than EV-A71 VLP to produce a
multivalent HFMD vaccine. Firstly, the use of HBcAg-VLP is more cost-effective, as HBcAg-VLP could
be produced in a bacterial expression system such as E. coli. This system will incur lower production
cost than yeast, insect, or mammalian cell expression systems that are required to produce the EV-A71
VLP. Secondly, HBcAg-VLP has a higher peptide insertion capacity (238 aa could be inserted in its
immune-dominant loop region) in comparison to EV-A71 VLP that could only receive a peptide of
around 20 amino acids in its BC loop region. Nonetheless, the suitability of HBcAg-VLP and EV-A71
VLP to carry multiple epitopes as an effective multivalent HFMD vaccine should be further tested.
5. Neutralizing Antibodies Against HFMD Etiological Agents
5.1. EV-A71 Neutralizing Antibodies
Neutralizing antibodies play major roles in immune-protection against viral infections. In EV-A71
infection, robust induction of EV-A71-specific IgM and IgG were detected during the first week of
infection and the responses peaked four to seven days after the onset of symptoms [66]. Passive
transfer of neutralizing anti-sera was reported to protect mice against lethal EV-A71 challenge,
indicating the importance of neutralizing antibodies in anti-EV-A71 immunity [46]. Importantly,
comprehensive understanding of the molecular basis of EV-A71 neutralization by antibodies would
aid in the rational design of an effective vaccine against EV-A71. In order to understand neutralizing
antibodies elicited by EV-A71, many groups generated neutralizing murine monoclonal antibodies
(mAbs) using immunogens, such as inactivated EV-A71, live EV-A71, EV-A71 VLPs, or the linear
neutralizing epitopes derived from EV-A71 (Table 2).
Table 2. Neutralizing monoclonal antibodies against EV-A71, CV-A16, CV-A6, and CV-A10.
Virus Name Epitope Type Epitope/Region Recognised Isotype Ref.
EV-A71
N1 Linear Recognized a section of the SP70 epitope. Neutralized 2subgenotypes tested (B4 and B5). IgG2a [67]
N3 Linear Recognized a section of the SP70 epitope. Neutralized 2subgenotypes tested (B4 and B5). IgG2a [67]
N4 Linear Recognized a section of the SP70 epitope. Neutralized 2subgenotypes tested (B4 and B5). IgG2a [67]
N6 Linear Recognized a section of the SP70 epitope. Neutralized 2subgenotypes tested (B4 and B5). IgG2a [67]
BB1A5 Linear
Recognized amino acids 136–155 in VP2
(AGGTGTEDSHPPYKQTQPGA). Neutralized B3, B4, C2 and
C5 subgenotypes.
IgG2a [28]
3D1 Unknown Recognized VP1. Neutralized all 8 subgenotypes tested (C1,C2, C3, C4, C5, B3, B4, and B5). IgM [68]
4E8 Unknown
Recognized two peptides P25 (aa2 40–250) and P26 (aa
250–260) of VP1. Neutralized C4 subgenotype (only
subgenotype tested).
IgG [69]
10D3 Conformational Recognized the knob region in VP3. Neutralized all 11subgenotypes of EV-A71. IgM [29]
mAb51 Linear Recognized a portion of the SP70 epitope (KQEKD).Neutralized all 11 subgenotypes of EV-A71. IgM [70]
2G8 Linear Recognized the SP70 epitope. Neutralized C4 subgenotype. IgM [71]
MA28-7 Conformational
Recognized the region comprising Gly145, Glu98, Lys242 and
Lys244 in VP1. Neutralized 6 genotypes tested (A, B1, B3, B4,
and C2).
N/A [72]
D6 Unknown Neutralized subgenotype C4 (only subgenotype tested). N/A [53]
A9 Unknown Neutralized subgenotype C4 (only subgenotype tested). N/A [53]
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Table 2. Cont.
Virus Name Epitope Type Epitope/Region Recognised Isotype Ref.
5H7 Conformational Recognized conformational epitope harbouring Ser74 in VP3.Neutralized all 11 subgenotypes tested. IgG [30]
D4 Unknown Neutralized subgenotype C4 (only subgenotype tested). IgG [73]
G12 Unknown Neutralized subgenotype C4 (only subgenotype tested). IgG [73]
22A12 Linear Neutralized subgenotype C4 (only subgenotype tested). IgG [74]
VP4N20
mAb Linear
Recognized the VP4N20 epitope in VP4. Neutralized EV-A71
tested (genogroup A and subgenotype C4) and CV-A16. N/A [35]
CV-A16
VP4N20
mAb Linear
Recognized the VP4N20 epitope in VP4. Neutralized EV-A71
tested (genogroup A and subgenotype C4) and CV-A16. N/A [35]
C33 Unknown Recognized the SP70 epitope. Neutralized genotype B ofCV-A16 (only one tested). N/A [53]
CV-A6 1D5 Conformational Recognized a region in VP1 comprising BC, DE, EF, and HIloops. IgG
[38,
39]
CV-A10 2G8 Conformational Recognized the VP1 C-terminus, VP2 EF loop, and VP3 ABloop. IgG [36]
N/A: Not reported.
Many of the EV-A71 neutralizing antibodies were generated by immunizing mice with live
EV-A71. For instance, Chang et al. (2011) inoculated mice with the live EV-A71/E59 genotype B4 strain
to generate mAbs [67]. The study identified four mAbs belonging to the IgG2a subclass designated as
N1, N3, N4, and N6. From epitope mapping studies, the four mAbs were found to recognize amino
acids 211 to 225 of the VP1 protein corresponding to the SP70 epitope. The mAbs were able to fully
cross-neutralize EV-A71 sub-genotypes B4 and B5 in the rhabdomyosarcoma (RD) cells and it was
noted that these mAbs could work synergistically, as complete inhibition was achieved at a markedly
lower concentration of the pooled mAbs in comparison to a single mAb in RD cells. In addition, Xu et al.
(2014) generated a mAb designated as BB1A5 belonging to the IgG2a isotype by immunizing mice
with the live EV-A71 strain 52-3 [28]. BB1A5 recognized a linear epitope spanning amino acids 136–155
in the VP2, and passive transfer of BB1A5 was able to provide 100% protection for the new-born
mice challenged with a mouse-adapted EV-A71 strain. Besides that, another group identified a mAb
designated as 3D1 belonging to the IgM isotype generated by immunizing mice with a mouse-adapted
EV-A71 strain [68]. They demonstrated that passive immunization using 3D1 prevented central
nervous system (CNS) infection. However, the exact binding site of 3D1 was unknown.
Additionally, inactivated EV-A71 was utilized to generate mAbs against EV-A71. For instance,
Chang et al. (2010) identified mAb 4E8, which was generated by immunizing mice with an inactivated
EV-A71 Henan2 (Hn2) genotype C4 strain [69]. Using synthetic peptide mapping, they identified
mAb 4E8 to recognize peptides containing amino acids 240–250 and 250–260 of VP1 by ELISA. In the
in vivo protection study, mAb 4E8 was able to provide partial protection against EV-A71 lethal
challenge in mice. In another study, Kiener et al. (2014) immunized mice with a binary ethyleneimine
(BEI)-inactivated EV-A71-B4 strain to generate mAb 10D3 belonging to the IgM isotype [29]. Dot blot
assay coupled with mutational analysis revealed that mAb 10D3 recognized a conformational epitope
at the highly conserved knob region of VP3. MAb 10D3 was able to confer in vivo passive protection
against EV-A71 infection. Moreover, neutralizing mAb51 belonging to the IgM isotype was generated
by immunizing mice with binary BEI-inactivated EV-A71 [70]. The mAb51 was able to provide 100%
in vivo passive protection in lethal challenge with EV-A71 in mice. Epitope mapping revealed that the
mAb51 targeted amino acids 215–219 in VP1, which is part of the SP70 epitope. Furthermore, Deng
et al. (2015) generated IgM isotype mAb designated as 2G8 by immunizing mice with heat-inactivated
EV-A71 [71]. The mAb was able to neutralize EV-A71 infection at the attachment stage. Biochemical
assays mapped the 2G8 epitope to the SP70 epitope. They also demonstrated that the L220A mutation
within the SP70 epitope completely abolished the ability of 2G8 to bind and neutralize EV-A71.
Another mAb designated as MA28-7 was generated by immunizing mice with formalin-inactivated
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EV-A71 strain 1095 [72]. Structural studies of MA28-7 in complex with EV-A71 revealed that the
mAb recognized a conformational epitope comprising several amino acids in VP1, including Gly145,
Glu98, Lys242, and Lys244. D6 and A9 were two other mAbs that were generated by immunization of
mice using inactivated EV-A71 [53]. Both mAbs were able to protect RD cells from EV-A71 infection.
Most recently, a mAb designated as 5H7 belonging to the IgG isotype was generated by immunizing
mice with inactivated EV-A71-B4 strain [30]. Epitope mapping revealed that 5H7 recognized a
conformational epitope within the VP3 protein harboring the highly conserved amino acid Ser74.
Interestingly, the highly conserved Ser74 is adjacent to the highly conserved knob region of VP3, which
was recognized by 10D3. MAb 5H7 was able to neutralize major EV-A71 genogroups, including A,
B4, C2, and C4. Chimeric 5H7 mAb was constructed by fusing the VH and VL regions of murine
mAb 5H7 to human kappa and IgG1 constant regions. Passive immunization using the resulting
mouse-human chimeric 5H7 protected 100% of mice challenged with EV-A71 B4 strain prophylactically
and therapeutically.
Other than live and inactivated viruses, VLPs have been used to generate mAbs. For example,
Lin et al. (2015) immunized mice with VLPs of EV-A71 produced in yeast [73]. From the immunization,
two mAbs were isolated, designated as D4 and G12. The mAbs bound to the VP1 of EV-A71, however,
the exact binding site of the mAbs was unknown. In an in vitro neutralization assay, both mAbs were
able to protect RD cells from CPE upon EV-A71 infection.
Several mAbs were generated by immunizing mice with synthetic peptides. For example, Li et al.
(2009) immunized mice using SP70 and SP55 peptides to isolate twelve IgG mAbs specific for SP70
and SP55 [74]. Out of the twelve mAbs, only mAb 22A12, which specifically recognized SP70 peptide,
provided complete protection of RD cells from EV-A71 viral infection at a neutralizing titre of 1:16,
albeit this titre was quite low in comparison to the 1:48 neutralization titre produced by antiserum from
rabbit immunized with the heat-inactivated virus [74]. In another study, a phage display technique
was used to produce a recombinant mAb targeting VP4N20 epitope in the VP4 protein [35]. In vitro
neutralizing assays revealed that the VP4N20 mAb prevented the development of cytopathic effects in
RD cells infected with either EV-A71 or CV-A16. This is consistent with the 90% amino acid identity of
VP4N20 epitope in both EV-A71 and CV-A16.
5.2. CV-A16, CV-A6 and CV-A10 Neutralizing Antibodies
Unlike EV-A71, few neutralization mAbs have been generated and identified against CV-A16,
CV-A6, and CV-A10. In a study performed by Ren et al. (2015), mAb C33 was generated by immunizing
mice with inactivated CV-A16 [53]. The mAb C33 was able to provide complete protection against the
development of cytopathic effects in Vero cells infected with CV-A16. For CV-A6, Yang et al. (2016)
immunized mice using live CV-A6 to generate mAbs [39]. They identified mAb 1D5 that could fully
protect mice from lethal CV-A6 challenge. The mAb also displayed good therapeutic effects in the mice
infected with CV-A6. Structural studies using cryo-electron microscopy revealed that mAb 1D5 bound
to the immune-dominant antigenic site within VP1 comprising the BC, DE, EF, and HI loops [38].
For CV-A10, a neutralizing mAb designated as 2G8 was obtained by immunizing mice with CV-A10
mature virions [36]. The mAb displayed high binding efficiency and potent neutralization activity
against CV-A10 infection based on ELISA and in vitro neutralization in RD cells. In vivo experiments in
the murine model revealed that 2G8 exhibited strong prophylactic and therapeutic properties, whereby
all mice administered with 2G8 before or after the CV-A10 lethal challenge survived. Structural
characterization using cryo-electron microscopy revealed that 2G8 recognized the VP1 C-terminus,
VP2 EF loop, and VP3 AB loop.
5.3. Neutralizing Antibodies as Potential Prophylactic or Therapeutic Agents against Enteroviruses Causing
HFMD
Antibodies can be administered as a therapeutic or prophylactic agent. Monoclonal antibody
therapy is crucial for immunocompromised individuals, as vaccinations are only suitable for
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individuals with an immune system capable of eliciting responses against the administered vaccine [75].
The antibodies to be used in mAb therapy should have high neutralizing efficacy coupled with broad
neutralizing spectrum against all or most of the viral subgenotypes. Ideally, the antibody therapy
should be able to neutralize multiple viruses causing the disease for it to be effective against multiple
etiological agents of HFMD.
As shown in Table 2, only four mAbs (3D1, 10D3, mAb51, and 5H7) were experimentally proven
to display broad neutralizing spectrum. Interestingly, three of the four mAbs, with the exception of
5H7, belonged to the IgM isotype. This observation is consistent with other studies and observations
made by several research groups that suggested antibody neutralizing capabilities were dependent
on their isotypes [71,75]. For example, Lim et al. (2012) reported that in contrast to the IgM isotype
that possessed neutralizing activity in vitro, IgG1 did not have neutralizing activity [70]. Besides
that, Liu et al. (2011) reported that IgG2a mAb displayed only modest neutralization activity against
EV-A71 [23]. Thus, it can be speculated that neutralizing capability of these mAbs is isotype-dependent.
In addition, three of the universally neutralizing mAbs, 10D3, 5H7, and mAb51, recognized a region
or a sequence that was highly conserved in all 11 subgenotypes, which was the knob region in VP3,
the highly conserved Ser74 adjacent to the knob region in VP3, and a short sequence in the SP70 epitope
(KQEKD), respectively [29,30,70]. This most likely contributes to their universal neutralizing capability.
Based on the evidence, it is possible that other mAbs, such as mAb VP4N20, which recognized an
epitope that is highly conserved in EV-A71 subgenotypes and in the CV-A16, might have a broad
neutralizing spectrum. However, neutralization by the mAb was only tested against limited EV-A71
subgenotypes. Therefore, it is imperative to further characterize the neutralizing spectrum of all the
mAbs identified so far to establish a comprehensive understanding of neutralizing mAbs against the
etiological agents of HFMD.
A major issue regarding the potential of using mAb clinically is that most of the mAbs were
derived from mice. Such mouse-derived mAbs would lead to immune rejection in humans, as they
might be recognized as foreign antigens by the human immune system [76]. Besides that, murine
mAbs were unable to induce downstream human immune responses due to the inability of human
immune cells, such as macrophages, to recognize the Fc region of murine mAbs. To circumvent
this problem, the humanization of murine mAbs is mandatory prior to passive immunization using
mouse-derived mAbs in humans. Taking dengue virus mAb513 as an example, which is currently
undergoing clinical trials in Singapore, few amino acid changes were made, including Thr33Val
mutation and Ser26 deletion, which resulted in the murine mAb 4E11 to be humanized [77]. In another
example, complementary determining region (CDR) grafting and variable (V) region replacement
were performed to convert the influenza virus subtype H5N1 antibody m8A8 to humanized 8A8 with
minimal murine immunogenicity [78]. Based on this evidence, it is possible to humanize murine mAbs
of enteroviruses for future medical applications (Table 2).
The design of an effective prophylactic mAb to prevent HFMD needs to account for the multiple
etiological agents that could be involved in HFMD outbreaks. The multi-domain antibody approach
could be an attractive approach to target several etiological agents of HFMD. Recently, there has been
one research group that designed a multi-domain antibody against multiple strains of influenza virus.
Laursen et al. (2018) linked multiple antibodies to design a prophylactic antibody against influenza
A and B strains designated as MD3606 [79]. MD3606 was able to confer protection in mice against
influenza A and influenza B infections. Thus, it may be possible to link four mAbs that were able to
neutralize each of the HFMD etiological agents (EV-A71, CV-A16, CV-A6, and CV-A10) to design a
tetravalent HFMD prophylactic antibody.
6. Conclusions
The global burden of HFMD is increasing and the trend will continue until an effective
vaccine against multiple HFMD causative agents is developed. Although there are three
formaldehyde-inactivated EV-A71 vaccines licensed by the China FDA, the inactivated monovalent
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vaccines are only protective against EV-A71 and not the other HFMD causative agents. Apart from
developing a bivalent EV-A71 and CV-A16 vaccine, research efforts are now focussed on developing a
multivalent HFMD vaccine. Comprehensive evaluations of humoral responses elicited by epitopes
from EV-A71, CV-A16, CV-A6, and CV-A10 are mandatory for a successful multivalent HFMD
vaccine development. The multivalent vaccine should provide protection against significant HFMD
Enterovirus A serotypes in a balanced manner and should ideally avoid the ADE effect. Future
studies to utilize other vaccine platforms, such as live-attenuated, recombinant protein subunit, viral
vectored, and peptide-based vaccines are needed, and will definitely open up new avenues to develop
fully efficacious and safe vaccines against HFMD. The multi epitope peptide-based HFMD vaccines
are gaining attention due to their safety, easy large-scale production, and low cost. With the rising
concern about the current HFMD outbreaks in Asia, the future will see more development of the
HFMD tetravalent vaccines, especially on a peptide-based multivalent HFMD vaccine platform, if low
immunogenicity of such vaccines could be overcome. Finally, further identification and generation
of neutralizing antibodies against etiological agents of HFMD are warranted, as prophylactic and
therapeutic antibodies against viruses are gaining popularity, as demonstrated in the development of
mAb therapies against dengue and influenza viruses.
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Abbreviations
ADE Antibody dependent enhancement
BEI Binary ethyleneimine
CDR Complementary Determining Region
CNS Central Nervous System
CV-A16 Coxsackievirus 16
EMEA European Medicine Agency
EV-A71 Enterovirus A 71
Fab Fragment antigen-binding
FcR Fc Receptor
FDA Food and Drug Administration
HFMD Hand, Foot and Mouth Disease
mTLNE Multiple tandem linear neutralizing epitope
RD Rhabdomyosarcoma
r.m.s.d Root Mean Square Deviation
RNA Ribonucleic Acid
Trx Thioredoxin
UTR Untranslated Region
VCV Varicella-zoster virus
VLP Virus-Like-Particle
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